



**Vivimed**

Date: 30/05/2016

To

BSE Limited  
P.J.Towers, Dalal Street,  
Mumbai – 400001

**BSE - Code : 532660**

National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051

**NSE- Symbol: VIVIMEDLAB**

**Sub.: Outcome of the Board Meeting held on May 30, 2016**

Dear Sir / Madam,

We wish to inform you that:

1. The Board of Directors (the Board") at its meeting held today i.e. May 30, 2016 has considered and approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2016. Please find enclosed said Audited Results along with Audit Report and Declaration as per Regulation 33 of the SEBI (LODR) (Amendment) Regulations, 2016
2. No Dividend is recommended for the Financial Year 2015-16
3. The meeting of the Board of Directors of the Company commenced at 2:30 P.M and concluded at 9:20 P.M .

Please take the above on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,  
For Vivimed Labs Ltd

  
Santosh Varalwar  
Managing Director



Vivimed Labs Ltd. (Corporate Office)

CIN : L02411KA1988PLC009465

Veernag Towers, Habsiguda, Hyderabad, Telangana - 500 007, India

T +91 (0) 40-2717 6005/6 F +91 (0) 40-2715 0599

contact@vivimedlabs.com www.vivimedlabs.com

**VIVIMED LABS LIMITED**  
STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2016

Rs in Lacs

| Sl. No.   | Particulars                                                                                                       | Quarter ended    |                  |                  | For the Year ended |                    |
|-----------|-------------------------------------------------------------------------------------------------------------------|------------------|------------------|------------------|--------------------|--------------------|
|           |                                                                                                                   | 31.03.2016       | 31.12.2015       | 31.03.2015       | 31.03.2016         | 31.03.2015         |
| <b>1</b>  | <b>Income From Operations</b>                                                                                     |                  |                  |                  |                    |                    |
|           | (a) Net Sales / Income from Operations (Net of Excise Duty)                                                       | 34,716.22        | 32,991.12        | 35,621.52        | 1,34,562.99        | 1,38,009.91        |
|           | (b) Other Operating Income                                                                                        | 288.52           | 196.77           | 49.75            | 1,080.98           | 586.57             |
|           | <b>Total Income From Operations (Net)</b>                                                                         | <b>35,004.73</b> | <b>33,187.89</b> | <b>35,671.27</b> | <b>1,35,643.97</b> | <b>1,38,596.49</b> |
|           | a. Cost of Raw Materials Consumed                                                                                 | 15,123.83        | 15,023.74        | 17,159.03        | 60,969.16          | 69,931.61          |
|           | b. Purchase of Stock in Trade                                                                                     |                  |                  |                  |                    |                    |
|           | c. Changes in Inventories of finished inventories of Finished Goods, Work-in-Progress and Stock in Trade          | 1,448.33         | 43.70            | (425.78)         | 1,435.62           | (5,309.20)         |
|           | d. Employee Benefit Expenses                                                                                      | 5,549.99         | 3,825.02         | 4,721.12         | 17,694.25          | 18,442.79          |
|           | e. Depreciation and Amortisation Expenses                                                                         | 1,477.06         | 1,545.04         | 1,470.70         | 6,139.34           | 6,617.76           |
|           | f. Other Expenditure                                                                                              | 7,759.18         | 8,169.44         | 8,954.15         | 31,255.74          | 33,256.12          |
| <b>2</b>  | <b>Total Expenses</b>                                                                                             | <b>31,358.38</b> | <b>28,606.94</b> | <b>31,879.21</b> | <b>1,17,494.10</b> | <b>1,22,939.08</b> |
| <b>3</b>  | <b>Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)</b>           | <b>3,646.35</b>  | <b>4,580.95</b>  | <b>3,792.06</b>  | <b>18,149.87</b>   | <b>15,657.41</b>   |
| <b>4</b>  | <b>Other Income</b>                                                                                               | -                | -                | -                | -                  | -                  |
| <b>5</b>  | <b>Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)</b>                | <b>3,646.35</b>  | <b>4,580.95</b>  | <b>3,792.06</b>  | <b>18,149.87</b>   | <b>15,657.41</b>   |
| <b>6</b>  | <b>Finance Costs</b>                                                                                              | 2,450.79         | 1,971.72         | 2,157.28         | 8,156.63           | 7,903.68           |
| <b>7</b>  | <b>Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)</b>          | <b>1,195.56</b>  | <b>2,659.23</b>  | <b>1,634.78</b>  | <b>9,993.24</b>    | <b>7,753.73</b>    |
| <b>8</b>  | <b>Exceptional Items</b>                                                                                          | -                | -                | -                | -                  | -                  |
| <b>9</b>  | <b>Profit / Loss from ordinary activities before Tax (7 - 8)</b>                                                  | <b>1,195.56</b>  | <b>2,659.23</b>  | <b>1,634.78</b>  | <b>9,993.24</b>    | <b>7,753.73</b>    |
| <b>10</b> | <b>Tax Expenses</b>                                                                                               | (65.12)          | 357.54           | (160.04)         | 1,625.93           | 548.69             |
| <b>11</b> | <b>Net Profit / Loss from ordinary activities after Tax (9 - 10)</b>                                              | <b>1,260.67</b>  | <b>2,301.69</b>  | <b>1,794.82</b>  | <b>8,367.32</b>    | <b>7,205.04</b>    |
| <b>12</b> | <b>Extraordinary Items (net of tax expenses Rs.....Lacs)</b>                                                      | -                | -                | -                | -                  | -                  |
| <b>13</b> | <b>Net Profit / Loss for period (11 - 12)</b>                                                                     | <b>1,260.67</b>  | <b>2,301.69</b>  | <b>1,794.82</b>  | <b>8,367.32</b>    | <b>7,205.04</b>    |
| <b>14</b> | <b>Share of Profit / (Loss) of associates</b>                                                                     | -                | -                | -                | -                  | -                  |
| <b>15</b> | <b>Minority Interest</b>                                                                                          | -                | -                | -                | -                  | -                  |
| <b>16</b> | <b>Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)</b> | <b>1,260.67</b>  | <b>2,301.69</b>  | <b>1,794.82</b>  | <b>8,367.32</b>    | <b>7,205.04</b>    |
| <b>17</b> | <b>Paid up Equity Share Capital (Face value of the Share shall be indicated)</b>                                  | 1,620.38         | 1,620.38         | 1,620.38         | 1,620.38           | 1,620.38           |
| <b>18</b> | <b>Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year</b>                    | -                | -                | -                | -                  | -                  |
| <b>19</b> | <b>Earnings per Share (before Extraordinary Items) (of Rs...../- each) (not annualised)</b>                       | 7.78             | 14.20            | 11.08            | 51.64              | 44.47              |
|           | (a) Basic                                                                                                         | 7.78             | 14.20            | 11.08            | 51.64              | 44.47              |
|           | (b) Diluted                                                                                                       | 7.55             | 13.78            | 10.74            | 50.09              | 43.13              |

- The above Consolidated Audited Financial Results for the Quarter & Year ended MARCH 31, 2016 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 30<sup>th</sup> MAY 2016
- Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Klar Sehen Private Limited, (iv) Octantis Nobel Labs Private Limited, (v) Vivimed Labs (Austria) private Limited (vi) Finaso Pharma private Limited (vii) Vivimed Specialty Chemicals Pvt Ltd viz (viii) Vivimed Holdings Limited and its stepdown subsidiary Vivimed Labs Europe Limited (ix) Vivimed Labs Mauritius Limited and its stepdown subsidiaries (i) Vivimed Labs UK Limited, (ii) Vivimed Labs Spain, S.L. (iii) Union Quimica Farmaceutica S.A.U., Spain, (iv) Holiday International Limited UK & (v) Uquifin Mexico S.A. de C.V.
- The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
- Corresponding numbers of previous period / year have been regrouped wherever necessary.
- Standalone Revenues impacted due to divestment of certain products within the specialty chemicals portfolio to Clariant India Limited
- The Company received Rs.258 crores towards part consideration of the deal with Clariant India Limited

Place : Hyderabad  
Date : 30.05.2016

For VIVIMED LABS LIMITED  
(SANTOSH JAGBALVAR)  
MANAGING DIRECTOR





VIVIMED LABS LIMITED

SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED

Rs in Lacs

| Particulars                                                                                           | 3 Months Ended          |                           |                         | FY 16<br>(Audited) | FY 15<br>(Audited) |
|-------------------------------------------------------------------------------------------------------|-------------------------|---------------------------|-------------------------|--------------------|--------------------|
|                                                                                                       | 31.03.2016<br>(Audited) | 31.12.2015<br>(Unaudited) | 31.03.2015<br>(Audited) |                    |                    |
| <b>1. Segment Revenue</b><br>(net sales/income from each segment should be disclosed under this head) |                         |                           |                         |                    |                    |
| a. Speciality Chemicals Business                                                                      | 9,449.86                | 8,685.91                  | 14,966.54               | 37,141.35          | 44,620.88          |
| b. Pharma Business                                                                                    | 25,266.36               | 24,305.20                 | 20,654.98               | 97,421.63          | 93,389.04          |
| <b>Total</b>                                                                                          | <b>34,716.22</b>        | <b>32,991.12</b>          | <b>35,621.52</b>        | <b>1,34,562.99</b> | <b>1,38,009.92</b> |
| Less, Inter Segment Revenue                                                                           |                         |                           |                         |                    |                    |
| <b>Net sales / Income from Operations</b>                                                             | <b>34,716.22</b>        | <b>32,991.12</b>          | <b>35,621.52</b>        | <b>1,34,562.99</b> | <b>1,38,009.92</b> |
| <b>2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>           |                         |                           |                         |                    |                    |
| a. Speciality Chemicals Business                                                                      | 1,212.21                | 2,111.07                  | 2,186.23                | 6,796.84           | 9,004.64           |
| b. Pharma Business                                                                                    | 2,434.13                | 2,567.67                  | 1,605.83                | 11,353.02          | 6,652.77           |
| <b>Total</b>                                                                                          | <b>3,646.35</b>         | <b>4,678.74</b>           | <b>3,792.06</b>         | <b>18,149.87</b>   | <b>15,657.41</b>   |
| Less: 1. Interest                                                                                     | 2,450.79                | 1,879.61                  | 2,157.28                | 8,156.63           | 7,903.68           |
| 2. Other Un-allocable Expenditure                                                                     |                         |                           |                         |                    |                    |
| 3. Un-allocable Income                                                                                |                         |                           |                         |                    |                    |
| <b>Total Profit Before Tax</b>                                                                        | <b>1,195.55</b>         | <b>2,799.12</b>           | <b>1,634.78</b>         | <b>9,993.24</b>    | <b>7,753.73</b>    |
| <b>3. Capital Employed</b>                                                                            |                         |                           |                         |                    |                    |
| a. Speciality Chemicals Business                                                                      | 84,539.58               | 74,152.66                 | 80,489.58               | 84,539.58          | 80,489.58          |
| b. Pharma Business                                                                                    | 70,862.31               | 66,437.84                 | 68,208.22               | 70,862.31          | 68,208.23          |
| <b>Total</b>                                                                                          | <b>1,55,401.89</b>      | <b>1,40,590.51</b>        | <b>1,48,697.80</b>      | <b>1,55,401.89</b> | <b>1,48,697.80</b> |

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
MANAGING DIRECTOR

Place : Hyderabad  
Date : 30.05.2016



**VIVIMED LABS LIMITED**  
STATEMENT OF STANDALONE AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2016

Rs in Lacs

| Sl. No.   | Particulars                                                                                                         | Quarter ended           |                           |                         | For the Year ended      |                         |
|-----------|---------------------------------------------------------------------------------------------------------------------|-------------------------|---------------------------|-------------------------|-------------------------|-------------------------|
|           |                                                                                                                     | 31.03.2016<br>(Audited) | 31.12.2015<br>(Unaudited) | 31.03.2015<br>(Audited) | 31.03.2016<br>(Audited) | 31.03.2015<br>(Audited) |
| <b>1</b>  | <b>Income From Operations</b>                                                                                       |                         |                           |                         |                         |                         |
|           | (a) Net Sales / Income from Operations (Net of Excise Duty)                                                         | 7,953.58                | 8,005.34                  | 12,641.27               | 31,939.36               | 43,014.81               |
|           | (b) Other Operating Income                                                                                          | 67.17                   | 1.03                      | 46.72                   | 98.38                   | 143.40                  |
|           | <b>Total Income from Operations (Net)</b>                                                                           | <b>8,020.75</b>         | <b>8,006.38</b>           | <b>12,687.99</b>        | <b>32,037.74</b>        | <b>43,158.21</b>        |
|           | a. Cost of Raw Materials Consumed                                                                                   | 3,274.09                | 2,877.17                  | 5,848.41                | 12,467.66               | 25,110.30               |
|           | b. Purchase of Stock in Trade                                                                                       | (12.99)                 | 318.20                    | 198.75                  | 686.79                  | (5,319.45)              |
|           | c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade            | 645.05                  | 619.67                    | 784.72                  | 2,399.35                | 2,788.34                |
|           | d. Employee Benefit Expenses                                                                                        | 534.45                  | 447.53                    | 492.55                  | 1,879.24                | 2,056.04                |
|           | e. Depreciation and Amortisation Expenses                                                                           | 2,144.49                | 1,993.65                  | 3,088.61                | 7,864.80                | 9,663.94                |
|           | f. Other Expenditure                                                                                                | 6,585.09                | 6,256.23                  | 10,413.04               | 25,297.84               | 34,499.17               |
|           | <b>Total Expenses</b>                                                                                               | <b>14,335.66</b>        | <b>13,501.15</b>          | <b>22,724.95</b>        | <b>67,399.00</b>        | <b>85,599.04</b>        |
| <b>2</b>  | <b>Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional Items (1 - 2)</b>             |                         |                           |                         |                         |                         |
| <b>3</b>  | <b>Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional Items (1 - 2)</b>             | <b>1,435.66</b>         | <b>1,750.15</b>           | <b>2,274.95</b>         | <b>6,739.90</b>         | <b>8,559.04</b>         |
| <b>4</b>  | <b>Other Income</b>                                                                                                 |                         |                           |                         |                         |                         |
| <b>5</b>  | <b>Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional Items (3 - 4)</b>                  | <b>1,435.66</b>         | <b>1,750.15</b>           | <b>2,274.95</b>         | <b>6,739.90</b>         | <b>8,559.04</b>         |
| <b>6</b>  | <b>Finance Costs</b>                                                                                                | <b>1,200.03</b>         | <b>1,410.94</b>           | <b>1,599.98</b>         | <b>5,605.93</b>         | <b>6,233.53</b>         |
| <b>7</b>  | <b>Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional Items (5 - 6)</b>            | <b>235.63</b>           | <b>339.21</b>             | <b>674.97</b>           | <b>1,133.96</b>         | <b>2,425.51</b>         |
| <b>8</b>  | <b>Exceptional Items</b>                                                                                            |                         |                           |                         |                         |                         |
| <b>9</b>  | <b>Profit / (Loss) from ordinary activities before Tax (7 - 8)</b>                                                  | <b>235.63</b>           | <b>339.21</b>             | <b>674.97</b>           | <b>1,133.96</b>         | <b>2,425.51</b>         |
| <b>10</b> | <b>Tax Expenses</b>                                                                                                 | <b>138.03</b>           | <b>67.84</b>              | <b>115.20</b>           | <b>321.16</b>           | <b>531.99</b>           |
| <b>11</b> | <b>Net Profit / Loss from ordinary activities after Tax (9 - 10)</b>                                                | <b>97.60</b>            | <b>271.37</b>             | <b>559.77</b>           | <b>812.80</b>           | <b>1,893.52</b>         |
| <b>12</b> | <b>Extraordinary Items (net of tax expenses Res.....lacs)</b>                                                       |                         |                           |                         |                         |                         |
| <b>13</b> | <b>Net Profit / Loss for period ( 11 - 12 )</b>                                                                     | <b>97.60</b>            | <b>271.37</b>             | <b>559.77</b>           | <b>812.80</b>           | <b>1,893.52</b>         |
| <b>14</b> | <b>Share of Profit / (Loss) of associates</b>                                                                       |                         |                           |                         |                         |                         |
| <b>15</b> | <b>Minority Interest</b>                                                                                            |                         |                           |                         |                         |                         |
| <b>16</b> | <b>Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates ( 13 - 14 - 15 )</b> | <b>97.60</b>            | <b>271.37</b>             | <b>559.77</b>           | <b>812.80</b>           | <b>1,893.52</b>         |
| <b>17</b> | <b>Paid up Equity Share Capital (Equity share of Rs. 10/- each)</b>                                                 | <b>1,620.38</b>         | <b>1,620.38</b>           | <b>1,620.38</b>         | <b>1,620.38</b>         | <b>1,620.38</b>         |
| <b>18</b> | <b>Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year</b>                      |                         |                           |                         |                         |                         |
| <b>19</b> | <b>Earnings per Share (before Extraordinary Items)</b>                                                              |                         |                           |                         |                         |                         |
|           | (a) Basic                                                                                                           | 0.60                    | 1.67                      | 3.45                    | 5.02                    | 11.69                   |
|           | (b) Diluted                                                                                                         | 0.58                    | 1.62                      | 3.35                    | 4.87                    | 11.34                   |

- The above Standalone Audited Financial Results for the Quarter & Year ended MARCH 31, 2016 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 30th MAY 2016
- The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.
- Revenues impacted due to divestment of certain products within its specialty chemicals portfolio to Clariant India Limited.
- The Company received Rs.258 crores towards part consideration of the deal with Clariant India Limited

Place : Hyderabad  
Date : 30.05.2016

For VIVIMED LABS LIMITED  
(SANTOSH VAKALWAR)  
MANAGING DIRECTOR





**VIVIMED LABS LIMITED**  
**SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED**

Rs in Lacs

| Particulars                                                                                           | 3 Months Ended          |                           |                         | FY 16<br>31.03.2016<br>(Audited) | FY 15<br>31-03-2015<br>(Audited) |
|-------------------------------------------------------------------------------------------------------|-------------------------|---------------------------|-------------------------|----------------------------------|----------------------------------|
|                                                                                                       | 31.03.2016<br>(Audited) | 31.12.2015<br>(Unaudited) | 31.03.2015<br>(Audited) |                                  |                                  |
|                                                                                                       |                         |                           |                         |                                  |                                  |
| <b>1. Segment Revenue</b><br>(net sales/income from each segment should be disclosed under this head) |                         |                           |                         |                                  |                                  |
| a. Speciality Chemicals Business                                                                      | 6,079.83                | 6,052.85                  | 10,866.81               | 24,113.40                        | 34,941.15                        |
| b. Pharma Business                                                                                    | 1,873.75                | 1,952.49                  | 1,774.46                | 7,825.96                         | 8,073.66                         |
| <b>Total</b>                                                                                          | <b>7,953.58</b>         | <b>8,005.34</b>           | <b>12,641.27</b>        | <b>31,939.36</b>                 | <b>43,014.81</b>                 |
| Less, Inter Segment Revenue                                                                           |                         |                           |                         |                                  |                                  |
| <b>Net sales / Income from Operations</b>                                                             | <b>7,953.58</b>         | <b>8,005.34</b>           | <b>12,641.27</b>        | <b>31,939.36</b>                 | <b>43,014.81</b>                 |
| <b>2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>           |                         |                           |                         |                                  |                                  |
| a. Speciality Chemicals Business                                                                      | 1,184.10                | 1,513.78                  | 2,000.46                | 5,918.33                         | 7,271.32                         |
| b. Pharma Business                                                                                    | 251.56                  | 236.37                    | 274.49                  | 821.58                           | 1,387.72                         |
| <b>Total</b>                                                                                          | <b>1,435.66</b>         | <b>1,750.15</b>           | <b>2,274.95</b>         | <b>6,739.90</b>                  | <b>8,659.04</b>                  |
| Less: 1. Interest                                                                                     | 1,200.03                | 1,410.94                  | 1,599.98                | 5,605.93                         | 6,233.53                         |
| 2. Other Un-allocable Expenditure                                                                     |                         |                           |                         |                                  |                                  |
| 3. Un-allocable Income                                                                                |                         |                           |                         |                                  |                                  |
| <b>Total Profit Before Tax</b>                                                                        | <b>235.63</b>           | <b>339.21</b>             | <b>674.97</b>           | <b>1,133.97</b>                  | <b>2,425.51</b>                  |
| <b>3. Capital Employed</b>                                                                            |                         |                           |                         |                                  |                                  |
| a. Speciality Chemicals Business                                                                      | 82,886.89               | 79,807.08                 | 81,345.51               | 82,886.89                        | 81,345.51                        |
| b. Pharma Business                                                                                    | 38,708.06               | 32,566.73                 | 31,889.23               | 38,708.06                        | 31,889.23                        |
| <b>Total</b>                                                                                          | <b>1,21,594.95</b>      | <b>1,12,373.81</b>        | <b>1,13,234.74</b>      | <b>1,21,594.95</b>               | <b>1,13,234.74</b>               |

Place : Hyderabad  
 Date : 30.05.2016

For VIVIMED LABS LIMITED  
 (SANTOSH VABALWAR)  
 MANAGING DIRECTOR



| S.No | Particulars                                | STANDALONE              |                         | CONSOLIDATED            |                         |
|------|--------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|      |                                            | As at                   | As at                   | As at                   | As at                   |
|      |                                            | 31.03.2016<br>(Audited) | 31.03.2015<br>(Audited) | 31.03.2016<br>(Audited) | 31.03.2015<br>(Audited) |
| (A)  | <b>EQUITY AND LIABILITIES</b>              |                         |                         |                         |                         |
| 1    | Shareholders funds                         |                         |                         |                         |                         |
|      | (a) Share Capital                          |                         |                         |                         |                         |
|      | i) Equity Share Capital                    | 1,620.38                | 1,620.38                | 1,620.38                | 1,620.38                |
|      | ii) Preference Share capital               |                         |                         | 6,394.56                | 6,394.56                |
|      | (b) Reserves and Surplus                   | 35,343.77               | 35,774.58               | 50,500.33               | 47,908.55               |
|      | (c) Money Received against Share Warrants  |                         |                         |                         |                         |
|      | <b>Sub Total Shareholders Funds</b>        | <b>36,964.15</b>        | <b>37,394.96</b>        | <b>58,515.28</b>        | <b>55,923.49</b>        |
| 2    | <b>Non-current liabilities</b>             |                         |                         |                         |                         |
|      | a) Long-term borrowings                    | 19,303.22               | 30,780.73               | 25,726.94               | 48,338.15               |
|      | (b) Deferred tax liabilities (net)         | 3,253.67                | 3,154.78                | 1,069.94                | 937.13                  |
|      | (c) Other long-term liabilities            | 32,103.98               | 12,282.80               | 28,956.50               | 4,243.81                |
|      | (d) Long-term provisions                   | 338.18                  | 301.05                  | 357.29                  | 316.96                  |
|      | <b>Sub-total - Non-current liabilities</b> | <b>54,999.05</b>        | <b>46,519.36</b>        | <b>56,110.66</b>        | <b>53,836.05</b>        |
| 3    | <b>Current liabilities</b>                 |                         |                         |                         |                         |
|      | (a) Short-term borrowings                  | 29,190.58               | 29,118.86               | 40,775.95               | 38,938.26               |
|      | (b) Trade payables                         | 2,444.97                | 4,560.86                | 16,673.97               | 18,871.38               |
|      | (c) Other current liabilities              | 11,408.28               | 10,166.27               | 28,585.38               | 17,637.68               |
|      | (d) Short-term provisions                  | 1,531.43                | 2,515.40                | 3,705.61                | 4,638.95                |
|      | <b>Sub-total - Current liabilities</b>     | <b>44,575.25</b>        | <b>46,361.39</b>        | <b>89,740.91</b>        | <b>80,086.27</b>        |
|      | <b>TOTAL - EQUITY AND LIABILITIES</b>      | <b>1,36,538.45</b>      | <b>1,30,275.71</b>      | <b>2,04,366.85</b>      | <b>1,89,845.81</b>      |
| (B)  | <b>ASSETS</b>                              |                         |                         |                         |                         |
| 1    | <b>Non-current assets</b>                  |                         |                         |                         |                         |
|      | (a) Fixed assets                           |                         |                         |                         |                         |
|      | (i) Tangible Assets                        | 37,623.54               | 36,466.11               | 71,490.93               | 69,629.81               |
|      | (ii) Intangible Assets                     | 1,070.25                | 1,189.17                | 9,925.89                | 11,717.24               |
|      | (iii) Capital work in progress             | 4,082.88                | 6,327.21                | 9,416.91                | 9,028.16                |
|      | (b) Non Current Investment                 | 23,004.56               | 23,004.55               | 268.92                  | 270.00                  |
|      | (c) Long Term Loans and advances           |                         |                         |                         |                         |
|      | (d) Other Non Current Assets               | -                       | -                       | 4.39                    | 4.37                    |
|      | <b>Sub-total - Non-current assets</b>      | <b>65,781.23</b>        | <b>66,987.04</b>        | <b>91,107.05</b>        | <b>90,649.59</b>        |
| 2    | <b>Current Assets</b>                      |                         |                         |                         |                         |
|      | (a) Inventories                            | 26,817.06               | 22,249.87               | 49,079.70               | 43,143.27               |
|      | (b) Trade receivables                      | 23,085.96               | 22,807.52               | 32,624.08               | 32,957.80               |
|      | (c) Cash and cash equivalents              | 717.56                  | 1,399.45                | 3,095.80                | 2,667.07                |
|      | (d) Short-term loans and advances          | 19,543.49               | 16,238.69               | 27,287.69               | 18,521.29               |
|      | (e) Other current assets                   | 593.14                  | 593.14                  | 1,172.53                | 1,906.78                |
|      | <b>Sub-total - Current assets</b>          | <b>70,757.22</b>        | <b>63,288.67</b>        | <b>1,13,259.80</b>      | <b>99,196.21</b>        |
|      | <b>TOTAL - ASSETS</b>                      | <b>1,36,538.45</b>      | <b>1,30,275.71</b>      | <b>2,04,366.85</b>      | <b>1,89,845.81</b>      |







**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

**Auditor's Report on Quarterly Consolidated Financial Results and Consolidated Year to Date Financial Results of Vivimed Labs Limited pursuant to the Regulation 33 of the SEBI ( Listing Obligations and Disclosures Requirements) Regulations, 2015.**

To  
Board of Directors  
Vivimed Labs Limited

We have audited the quarterly consolidated financial results of Vivimed Labs Limited (the company) and its subsidiaries (collectively referred to as "The Group") for the quarter ended 31<sup>st</sup> March, 2016 and the consolidated year to date results for the period from 01<sup>st</sup> April, 2015 to 31<sup>st</sup> March, 2016 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The quarterly consolidated financial results and consolidated year to date financial results have been prepared from consolidated interim financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on the Consolidated financial results based on our audit of such Consolidated interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS) 25, specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

We did not audit the financial statements and financial information of the Subsidiary Companies which are included in the consolidated quarterly financial results and consolidated year to date results, whose consolidated interim financial statements reflect total assets of Rs. 21,84,76,66,250/- as at 31<sup>st</sup> March, 2016 as well as the total revenue of Rs. 10,63,43,97,867/- as at 31<sup>st</sup> March, 2016. These include Audited Interim financial statements and other financial information in respect of some of the subsidiaries whose audit reports are yet to be received and whose financial information and statements have been furnished to us by the management, and our opinion on the quarterly financial results and the year to date results, to the extent they have been derived from such interim financial statements is based solely on such audited financial statements and other financial information.





**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

In our opinion and to the best of our information and according to the explanations given to us these consolidated quarterly financial results as well as the consolidated year to date financial results:


1. Include the quarterly and year to date financial results of the following entities;

- a. Octanttis Nobel Labs Pvt Limited
- b. Creative Health Care Private Limited
- c. Klar Sehen Private Limited
- d. Finoso Pharma Private Limited
- e. Vivimed Alathur Private Limited
- f. Vivimed Holdings Limited, Hong Kong
- g. Vivimed Labs Europe Limited, UK
- h. Vivimed Lab USA Inc., USA
- i. Vivimed Labs Spain SL
- j. Union Quimico Farmaceutica SAU, Spain
- k. Uquifa Mexico S A de C.V
- l. Vivimed Labs Mauritius Limited
- m. Holiday International Limited
- n. Vivimed Labs UK Limited, UK

2. have been presented in accordance with the requirements of Regulation 33 of the SEBI(Listing Obligations and Disclosures Requirements) Regulations, 2015 in this regard; and
3. give a true and fair view of the net profit and other financial information for the quarter ended 31st March 2016, as well as the year to date results for the period from 1st April 2015 to 31st March 2016.

Place: Hyderabad  
Date: 30-05-2016

For P. Murali & Co.,  
Chartered Accountants  
FRN: 007257S

  
A Krishna Rao  
Partner

M No. 020085







**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

**Auditor's Report on Quarterly Financial Results and Year to Date  
Financial Results of Vivimed Labs Limited pursuant to the Regulation  
33 of the SEBI ( Listing Obligations and Disclosures Requirements)  
Regulations, 2015.**

To  
The Board of Directors  
Vivimed Labs Limited

1. We have audited the quarterly financial results of Vivimed labs Limited for the quarter ended March 31, 2016 and to the year to date financial results for the year ended March 31, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. The quarterly financial results are the derived figures between the audited figures in respect of the year ended March 31, 2016 and the published year-to-date figures up to December 31, 2015, being the date of the end of the third quarter of the current financial year, which were subject to limited review. The financial results for the quarter ended March 31, 2016 have been prepared on the basis of the financial results for the nine-month period ended December 31, 2015, the audited annual financial statements as at and for the year ended March 31, 2016, and the relevant requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these Financial results based on our review of the financial results for the nine-month period ended December 31, 2015 which was prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, specified under section 133 of the act, read with rule 7 of the companies (Accounts) Rules 2014 and other accounting principles generally accepted in India; our audit of the annual financial statements as at and for the year ended March 31, 2016; and the relevant requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.






**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

3. In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date financial results:
- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI(Listing Obligations and Disclosures Requirements) Regulations, 2015 in this regard; and
  - (ii) give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2016 as well as the year to date results for the period from April 1, 2015 to March 31, 2016.
4. Further, read with paragraph 1 above, we report that the figures for the quarter ended March 31, 2016 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2016 and the published year-to-date figures up to December 31, 2015, being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated in paragraph 1 above, as required under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
5. Further, read with paragraph 1 above, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For P. Murali & Co.,  
Chartered Accountants  
Firm's Registration number: 007257S

  
A Krishna Rao  
Partner  
M.No. 020085



Place: Hyderabad  
Date: 30-05-2016





**Vivimed**

Date: 30/05/2016

To

BSE Limited  
P.J.Towers, Dalal Street,  
Mumbai – 400001

**BSE - Code : 532660**

National Stock Exchange of India Ltd.  
Exchange Plaza,Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051

**NSE- Symbol: VIVIMEDLAB**

**Sub.: Declaration – reg**

**Ref: Regulation 33 of the SEBI (LODR) (Amendment) Regulations, 2016**

Pursuant to the requirement as specified under Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations ,2015 as amended by SEBI ((Listing Obligations and Disclosure Requirements) (amendment) Regulations 2016, it is hereby declared that the Auditors Report for the financial year ended as on March 31,2016 contains unmodified opinion as provided under the independent Auditors Report which is attached herewith for your reference.

Please take the above on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,  
**For Vivimed Labs Ltd**

  
**Ramesh Challa**  
Chief Financial Officer



**Vivimed Labs Ltd. (Corporate Office)**

CIN : L02411KA1988PLC009465

Veernag Towers, Habsiguda, Hyderabad, Telangana - 500 007, India

T +91 (0) 40-2717 6005/6 F +91 (0) 40-2715 0599

contact@vivimedlabs.com www.vivimedlabs.com